{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-063699","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.225336+00:00","generated_at":"2026-06-27T02:05:18.392623+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cullinan Oncology hires Jeffrey Jones as CMO and appoints Anne-Marie Martin to board","bullets":["Jeffrey Jones, M.D., MPH, MBA, appointed CMO effective Feb 28, 2022; previously VP at Bristol Myers Squibb.","Annual base salary $460,000; sign-on bonus $100,000; option for 215,000 shares at $14.34.","Dr. Jones' option vests 25% on first anniversary, remainder monthly over three years.","Anne-Marie Martin, Ph.D., appointed Class I director effective Mar 1, 2022; SVP at GlaxoSmithKline.","Dr. Martin received option grant with grant-date fair value $350,000 vesting over three years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-063699","json":"https://secwatch.observer/filing/0001193125-22-063699.json","markdown":"https://secwatch.observer/filing/0001193125-22-063699.md","text":"https://secwatch.observer/filing/0001193125-22-063699.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522063699/0001193125-22-063699-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522063699/d303753d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:05:18.392623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"410668c7d4","claim":"Jeffrey Jones was appointed as Chief Medical Officer at Cullinan Therapeutics, Inc..","evidence_excerpt":"On February 28, 2022, Cullinan Oncology, Inc. (the “Company”) announced the hiring and appointment of Jeffrey Jones, M.D., MPH, MBA as the Company’s Chief Medical Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522063699/0001193125-22-063699-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}